Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00285428 · ClinicalTrials.gov registry record · Phase 1
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
A Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 3
- Study locations
NCT00285428: Completed Phase 1 study of Non-Hodgkin's Lymphoma, sponsored by Gilead Sciences.
NCT00285428 is a Phase 1 study of Non-Hodgkin's Lymphoma that has completed, run by Gilead Sciences. The registered enrollment target is 82 participants, below the 220-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (63% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00285428, a Phase 1 study of Non-Hodgkin's Lymphoma, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.
Conditions Studied
Interventions
- DRUG hA20-humanized anti-CD20 antibody
Study Locations (3)
New York
- New York Presbyterian Hospital/Cornell Medical Center - New York
Pennsylvania
- University Hospital of Pennsylvania - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2004-09 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
What the finished NCT00285428 record still lists
NCT00285428 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 220-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which hA20-humanized anti-CD20 antibody is the first listed.
NCT00285428 reports a single indexed study location in New York, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT00285428 about?
NCT00285428 is a clinical study titled "Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma". This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.
What is the current status of trial NCT00285428?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2004-09. Estimated completion is 2007-10.
What conditions does trial NCT00285428 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00285428?
The interventions under investigation include: hA20-humanized anti-CD20 antibody (DRUG).
Who is sponsoring clinical trial NCT00285428?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00285428 being conducted?
This trial has 3 study locations across New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00285428's enrollment target sits among peer trials
82 21st of 63 higher than 42 of 63 other Non-Hodgkin's Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin's Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
-
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia